Skip to main content
Evidence Snapshot

Ishikawa

CHEMBL614649 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:35:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614649
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ishikawa as ChEMBL target CHEMBL614649. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ishikawa
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614649
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Ishikawa matters

As of 2026-09-13

Ishikawa is reviewed as Ishikawa; the current evidence base includes 15 approved drugs, 745 compounds, and 160 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 745 compounds, and 160 assays for this target. The dominant activity type is IC50. CHEMBL135 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL135 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Ishikawa matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

745
Total Compounds
160
Total Assays
15
Approved Drugs
IC50: 470.0, KI: 29.0, EC50: 63.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL135
 11.0 EC50 Approved
No preferred name
CHEMBL81
 10.4 EC50 Approved
No preferred name
CHEMBL1628161
 10.1 EC50 Clinical
No preferred name
CHEMBL1627715
 10.1 Ki —
No preferred name
CHEMBL9225
 10.0 EC50 Approved

Approved Drugs

Structure Compound First Approval
NIRAPARIB
CHEMBL1094636
 2017
RALOXIFENE
CHEMBL81
 1997
PACLITAXEL
CHEMBL428647
 1992
MITOXANTRONE
CHEMBL58
 1987
TAMOXIFEN
CHEMBL83
 1977
ESTRADIOL
CHEMBL135
 1975
DOXORUBICIN
CHEMBL53463
 1974
HEXESTROL
CHEMBL9225
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:35:17Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614649